Quantcast

Industry news that matters to you.  Learn more

Quanterix Marks Leadership in Accelerating Neurology Research with 100-Publication Milestone

Reading time: 3 – 4 minutes

Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, recently announced it has surpassed an important milestone that its technology has been highlighted in more than 100 third-party, peer-reviewed publications in neurology. Driven by increased demand for the company’s Simoa technology, which continues to prove itself as the industry standard for ultra-sensitive biomarker detection, this brings the total number of publications for the company to over 215 across neurology, oncology, cardiology, inflammation and infectious disease.

“This is an incredible moment for Quanterix and further validation of our mission as a research-backed company that puts science first,” said Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix. “It’s also an important time for precision health, as publication results continue to confirm precision medicine as a more effective method for diagnosing and treating diseases. We are honored that many of the world’s leading researchers and academics are increasingly choosing to partner with us for the sensitivity and specificity that only our technology can provide.”

The most recent studies powered by Simoa in this therapeutic category are evidence of breakthroughs that could change the way medical professionals diagnose and treat neurological disorders, and potentially prevent many of them from presenting. Recent impactful studies include:

For more information on Quanterix’ complete list of publications and posters, please visit: https://www.quanterix.com/resources/publications-posters

Source: Business Wire